Cipla的利润下跌了57%, 原因是美国林业发展局停业, 价格压力, 和收购成本, 缺少估计。 Cipla's profit plunged 57% due to a U.S. FDA shutdown, pricing pressure, and acquisition costs, missing estimates.

由于美国FDA在Lanreotide工厂的生产停止,价格压力和收购成本,Cipla的净利同比下降了57%,在FY26第三季度降至676亿卢比,但没有达到预期. Cipla's net profit fell 57% year-on-year to ₹676 crore in the third quarter of FY26, missing expectations, due to a U.S. FDA-mandated production halt at its Lanreotide facility, pricing pressure, and costs from acquisitions. 北美收入下降了22%,达到1,485克朗,而印度在慢性病治疗方面的强劲表现则提高了10%的销售额。 North America revenue dropped 22% to ₹1,485 crore, while India’s sales rose 10% on strong performance in chronic disease therapies. 公司的总收入为7,074亿卢比,EBITDA下降了37%,股价下降了4%. Overall revenue was flat at ₹7,074 crore, EBITDA fell 37%, and shares dropped 4%. 该公司预计未来产品将启动,以推动回收。 The company expects future product launches to drive recovery.